ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0176

Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis

Kastriot Kastrati1, Nasim NAKHOST LOTFI2, Marwa Tawfik3, Ellen Gelpi2, Romana Hoeftberger2, Hans-Peter Kiener2, Daniel Aletaha4, Michael Bonelli5 and Helga Radner5, 1Division of Rheumatology, Vienna, Austria, 2Medical University Vienna, Vienna, Austria, 3Suez Canal University, Ismailia, Egypt, 4Medical University Vienna, Wien, Austria, 5Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Meeting: ACR Convergence 2022

Keywords: dermatomyositis, Inflammation, Myopathies, Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Muscle Biology, Myositis and Myopathies Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Diagnosis of idiopathic inflammatory myopathies (IIM) represents a clinical challenge and muscle biopsy is regarded as a fundamental procedure for confirming diagnosis. However, the significance of muscle biopsy as diagnostical technique remains inconclusive. The aim of this study was to evaluate the diagnostic accuracy, performance, and clinical relevance of muscle biopsy in patients with suspected myositis.

Methods: Results of muscle biopsies of adult patients with clinically suspected or differential diagnosis of myositis referred from all over Austria to the Medical University of Vienna between 2007-2021 were analyzed. Information was extracted from handwritten assignment sheets, including suspected diagnosis (inflammatory and/or non-inflammatory myopathy), referral department, sampling location, demographic, clinical, laboratory and serologic data, and imaging results. Histological findings were grouped in: 1) inflammatory, 2) non-inflammatory (neurogenic, metabolic etc.), 3) inflammatory and non-inflammatory mixed, and 4) normal.

Clinical information including symptoms, laboratory results, medication, and imaging were retrieved form electronical medical records (EMR). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of final histological results were calculated using diagnosis by the clinician and initiation/escalation of immunosuppressive therapy as gold standards.

Results: Out of 758 patients with muscle biopsy, 527 (69.5%) were referred with the suspected diagnosis of myositis only and 231 (30.5%) were referred with the differential diagnosis of myositis. Out of 527 samples with suspected diagnosis of myositis only, diagnosis was confirmed histologically in 249 (47.3%) cases; 39/527 (7.4%) specimen additionally showed co-features of non-inflammatory myopathy, whereas 221 (41.9%) were non-inflammatory at all. Out of 231 samples with differential diagnosis of non-inflammatory myopathies in addition to myositis, 52 (22.5%) were histologically inflammatory only and 17 (7.4%) showed mixed features. 151 (65.4%) biopsies were exclusively non-inflammatory.
Probability of histopathological diagnosis of inflammatory myopathy declined significantly, when CK levels were normal or myositis was stated as differential diagnosis. High clinical probability of myositis (muscular symptoms, elevated CK and MRI and/or EMG suggestive for myopathy) was indicative for myositis in biopsy (64.3%). Overall sensitivity and specificity of muscle biopsy were 82% when diagnosis by the clinician was set as gold standard. When initiation of immunosuppression is considered gold standard, a decline of sensitivity and specificity was observed. Pathological results suggestive for myositis (elevated CK levels, positive autoantibodies and pathologic EMG/MRI) led to decrease of specificity and negative predictive value (figure 1).

Conclusion: If myositis was suspected only or as differential diagnosis, approximately 47% of the biopsies revealed an inflammatory myopathy. Sensitivity and specificity of biopsy was moderate to high when using start of immunosuppression or diagnosis by the clinician as gold standard for IIM diagnosis.

Supporting image 1

Table 1. Patient characteristics

Supporting image 2

Figure 1. Performance of muscle biopsy with different gold standards.


Disclosures: K. Kastrati, None; N. NAKHOST LOTFI, None; M. Tawfik, None; E. Gelpi, None; R. Hoeftberger, None; H. Kiener, None; D. Aletaha, Novartis, SoBi, Sanofi, Amgen, Lilly, Merck, Pfizer, Roche, Sandoz, Janssen, AbbVie; M. Bonelli, Eli Lilly; H. Radner, None.

To cite this abstract in AMA style:

Kastrati K, NAKHOST LOTFI N, Tawfik M, Gelpi E, Hoeftberger R, Kiener H, Aletaha D, Bonelli M, Radner H. Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/diagnostic-accuracy-and-clinical-relevance-of-muscle-biopsy-in-patients-with-suspected-myositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-accuracy-and-clinical-relevance-of-muscle-biopsy-in-patients-with-suspected-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology